Holen Sie sich die Stockscreener-App
10.06
4.03%
0.39
Handel nachbörslich:
10.34
0.28
+2.78%
Schlusskurs vom Vortag:
$9.67
Offen:
$9.79
24-Stunden-Volumen:
972.09K
Relative Volume:
0.97
Marktkapitalisierung:
$1.07B
Einnahmen:
$247.00M
Nettoeinkommen (Verlust:
$-249.00M
KGV:
-3.2557
EPS:
-3.09
Netto-Cashflow:
$-267.00M
1W Leistung:
+6.01%
1M Leistung:
+7.82%
6M Leistung:
-20.79%
1J Leistung:
-35.68%
1-Tages-Spanne:
$9.74
$10.23
1-Wochen-Bereich:
$8.88
$10.74
52-Wochen-Spanne:
$6.50
$18.98
Arcus Biosciences Inc Stock (RCUS) Company Profile
Firmenname
Arcus Biosciences Inc
Sektor
Branche
Telefon
(510) 694-6200
Adresse
3928 POINT EDEN WAY, HAYWARD, CA
Vergleichen Sie RCUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
10.06 | 1.03B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-10-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2020-04-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-09-27 | Eingeleitet | Mizuho | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2018-10-09 | Eingeleitet | Wedbush | Outperform |
| 2018-04-09 | Eingeleitet | Citigroup | Buy |
| 2018-04-09 | Eingeleitet | Goldman | Neutral |
| 2018-04-09 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Arcus Biosciences Inc Aktie (RCUS) Neueste Nachrichten
Will Arcus Biosciences Inc. Hold Gains Into CloseReliable Alerts for Daily Stock Movers Released - beatles.ru
Arcus Biosciences Q2 Earnings and Catalysts Ahead: A Risky Buy for 12 Months - AInvest
Arcus BiosciencesA Risky Buy Ahead Of Pivotal, Catalyst Rich 12 Months (NYSE:RCUS) - Seeking Alpha
Trapped Investors in Arcus Biosciences Inc. Await Breakout SignalNews Based Entry Opportunity Alerts Detected - beatles.ru
Arcus Biosciences, Inc. (NYSE:RCUS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Arcus Biosciences Inc. Stock Recovery Path — Analyst BreakdownReal Time Stock Movement Analysis Indicates Breakout - beatles.ru
Gilead and Arcus Advance Promising Colorectal Cancer Study - TipRanks
Arcus Biosciences Tops Revenue Forecasts And Drives Pipeline Growth - Finimize
Gilead and Arcus Biosciences’ Promising Study on Advanced Gastrointestinal Cancers - TipRanks
A Quick Look at Today's Ratings for Arcus Biosciences(RCUS.US), With a Forecast Between $14 to $52 - 富途牛牛
Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2 - MSN
Wells Fargo Adjusts Price Target for Arcus Biosciences (RCUS) | - GuruFocus
H.C. Wainwright Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
Morgan Stanley Lifts Price Target on Arcus Biosciences to $23 From $22, Keeps Overweight Rating - MarketScreener
Decoding Arcus Biosciences Inc (RCUS): A Strategic SWOT Insight - GuruFocus
Arcus Biosciences Reports Strong Q2 2025 Results - TipRanks
Arcus Biosciences earnings beat by $0.01, revenue topped estimates - Investing.com Canada
Arcus Biosciences Q2 revenue beats analyst expectations - MarketScreener
Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update - Stock Titan
Is Arcus Biosciences (NYSE:RCUS) Using Debt In A Risky Way? - 富途牛牛
When is Arcus Biosciences Inc. stock expected to show significant growthIdentify undervalued stocks ready to soar - Jammu Links News
How volatile is Arcus Biosciences Inc. stock compared to the marketTremendous gains - Jammu Links News
What are the technical indicators suggesting about Arcus Biosciences Inc.Free Wealth Planning Blueprint - Jammu Links News
What institutional investors are buying Arcus Biosciences Inc. stockHigh-yield investments - Jammu Links News
Should I hold or sell Arcus Biosciences Inc. stock in 2025Unlock powerful portfolio management tools - Jammu Links News
How does Arcus Biosciences Inc. compare to its industry peersOutstanding capital appreciation - Jammu Links News
What are the latest earnings results for Arcus Biosciences Inc.Outstanding risk-reward balance - Jammu Links News
Why is Arcus Biosciences Inc. stock attracting strong analyst attentionRealize consistent double-digit growth - Jammu Links News
Does Arcus Biosciences Inc. stock perform well during market downturnsTremendous gains - Jammu Links News
What catalysts could drive Arcus Biosciences Inc. stock higher in 2025Free Stock Movement Tracking - Jammu Links News
Arcus Biosciences’ Pancreatic Cancer Drug Quemliclustat Receives Orphan Drug Designation from FDA - MSN
How does Arcus Biosciences Inc. generate profit in a changing economyPost Market Planner That Work - Jammu Links News
Arcus Biosciences Advances Phase 1 Study of AB521 in Cancer Treatment - TipRanks
Will Arcus Biosciences Inc. bounce back from current supportEarly Breakout Entry Point Notifications Sent - metal.it
Why Arcus Biosciences Inc. stock attracts strong analyst attentionConsistent Income Focused Trade List Analyzed - beatles.ru
How many analysts rate Arcus Biosciences Inc. as a “Buy”Advanced Screener Report With Low Risk - Jammu Links News
Arcus Biosciences’ Phase 3 Trial: A Potential Game-Changer in Pancreatic Cancer Treatment - TipRanks
Arcus Biosciences Inc.’s Price Action Aligns with Quant SignalsHigh Yield Stock Screening Results Explained - metal.it
Arcus Biosciences’ SWOT analysis: HIF-2alpha program drives stock outlook By Investing.com - Investing.com South Africa
Arcus Biosciences Inc. Shows Risk Reward Favoring UpsideReal Trader Watchlist of Hot Stocks Released - metal.it
Is it the right time to buy Arcus Biosciences Inc. stockSuperior returns - Jammu Links News
What is Arcus Biosciences Inc. company’s growth strategyMaximize your portfolio’s growth potential - Jammu Links News
Finanzdaten der Arcus Biosciences Inc-Aktie (RCUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):